Biotech Jumps After Rival Pushes Back Depression Drug Tests
Sage jumped Tuesday after rival Marinus said it would delay top-line results of a Phase 2 study in postpartum depression.
Sage jumped Tuesday after rival Marinus said it would delay top-line results of a Phase 2 study in postpartum depression.